Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results

Amneal Pharmaceuticals (NASDAQ:AMRX) posted its quarterly earnings results on Thursday. The company reported $0.27 earnings per share for the quarter, FiscalAI reports. Amneal Pharmaceuticals had a negative return on equity of 276.67% and a net margin of 4.53%.The firm had revenue of $722.52 million for the quarter.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX traded down $0.13 during mid-day trading on Friday, hitting $13.60. 167,157 shares of the company’s stock traded hands, compared to its average volume of 2,292,184. Amneal Pharmaceuticals has a 1 year low of $7.02 and a 1 year high of $15.42. The company has a market cap of $4.28 billion, a PE ratio of 35.78 and a beta of 1.32. The firm’s 50 day simple moving average is $12.82 and its 200 day simple moving average is $12.73.

Wall Street Analysts Forecast Growth

AMRX has been the subject of a number of research analyst reports. Truist Financial increased their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reiterated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price target for the company. Finally, Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Institutional Trading of Amneal Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Kemnay Advisory Services Inc. purchased a new stake in shares of Amneal Pharmaceuticals in the fourth quarter valued at about $26,000. Federated Hermes Inc. grew its holdings in Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after purchasing an additional 2,168 shares during the period. Spire Wealth Management grew its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock valued at $32,000 after purchasing an additional 1,023 shares during the period. Transamerica Financial Advisors LLC grew its holdings in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares during the period. Finally, Comerica Bank grew its holdings in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after purchasing an additional 1,957 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.